VANCENASE AQ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vancenase Aq, and what generic alternatives are available?
Vancenase Aq is a drug marketed by Schering and is included in two NDAs.
The generic ingredient in VANCENASE AQ is beclomethasone dipropionate monohydrate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the beclomethasone dipropionate monohydrate profile page.
Summary for VANCENASE AQ
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 65 |
Clinical Trials: | 2 |
Patent Applications: | 5,329 |
DailyMed Link: | VANCENASE AQ at DailyMed |
Recent Clinical Trials for VANCENASE AQ
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fred Hutchinson Cancer Research Center | Phase 2 |
Merck Sharp & Dohme Corp. | Phase 3 |
US Patents and Regulatory Information for VANCENASE AQ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | VANCENASE AQ | beclomethasone dipropionate monohydrate | SPRAY, METERED;NASAL | 019589-001 | Dec 23, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Schering | VANCENASE AQ | beclomethasone dipropionate monohydrate | SPRAY, METERED;NASAL | 020469-001 | Jun 26, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |